Recap: Zymeworks Q3 Earnings
Portfolio Pulse from Benzinga Insights
Zymeworks (NASDAQ:ZYME) reported its Q3 earnings results, beating estimated earnings by 19.15% with an EPS of $-0.38 versus an estimate of $-0.47. Revenue was up $13.88 million from the same period last year. However, last quarter the company missed on EPS by $0.28, which was followed by a 7.6% drop in the share price the next day.
November 07, 2023 | 9:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Zymeworks beat Q3 earnings estimates, which could positively impact the stock. However, investors may remain cautious due to the previous quarter's missed EPS and subsequent share price drop.
Zymeworks' Q3 earnings beat estimates, which is typically a positive signal for the stock. However, the company's miss on EPS in the previous quarter and the subsequent drop in share price may make investors cautious, potentially limiting any immediate positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100